DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $764,149 | +8.4% | 3,080 | +4.8% | 0.18% | +5.4% |
Q2 2023 | $705,120 | -6.1% | 2,938 | -1.4% | 0.17% | -16.8% |
Q1 2023 | $750,847 | -4.5% | 2,979 | +0.6% | 0.20% | -11.0% |
Q4 2022 | $786,174 | -27.3% | 2,962 | -29.2% | 0.23% | -34.2% |
Q3 2022 | $1,081,000 | +0.2% | 4,184 | -1.7% | 0.34% | +4.5% |
Q2 2022 | $1,079,000 | -41.6% | 4,255 | -32.5% | 0.33% | -33.2% |
Q1 2022 | $1,848,000 | -13.8% | 6,300 | -3.3% | 0.49% | -6.6% |
Q4 2021 | $2,144,000 | +514.3% | 6,516 | +469.1% | 0.53% | +413.6% |
Q3 2021 | $349,000 | +38.5% | 1,145 | +21.9% | 0.10% | +41.1% |
Q2 2021 | $252,000 | +20.0% | 939 | +0.4% | 0.07% | +15.9% |
Q1 2021 | $210,000 | +0.5% | 935 | -0.8% | 0.06% | -4.5% |
Q4 2020 | $209,000 | +2.0% | 943 | -1.2% | 0.07% | -7.0% |
Q3 2020 | $205,000 | +13.3% | 954 | -6.7% | 0.07% | +20.3% |
Q2 2020 | $181,000 | +26.6% | 1,023 | -1.0% | 0.06% | +9.3% |
Q1 2020 | $143,000 | -9.5% | 1,033 | +0.6% | 0.05% | +17.4% |
Q4 2019 | $158,000 | +13.7% | 1,027 | +7.0% | 0.05% | +2.2% |
Q3 2019 | $139,000 | -2.8% | 960 | -4.3% | 0.04% | -2.2% |
Q2 2019 | $143,000 | +10.0% | 1,003 | +1.5% | 0.05% | +4.5% |
Q1 2019 | $130,000 | +23.8% | 988 | -2.8% | 0.04% | +15.8% |
Q4 2018 | $105,000 | +69.4% | 1,016 | +76.7% | 0.04% | +81.0% |
Q3 2018 | $62,000 | -36.7% | 575 | -42.3% | 0.02% | -41.7% |
Q2 2018 | $98,000 | +6.5% | 996 | +6.3% | 0.04% | +2.9% |
Q1 2018 | $92,000 | +8.2% | 937 | +2.0% | 0.04% | +12.9% |
Q4 2017 | $85,000 | +97.7% | 919 | +85.3% | 0.03% | +82.4% |
Q3 2017 | $43,000 | +7.5% | 496 | +5.8% | 0.02% | +6.2% |
Q2 2017 | $40,000 | -42.0% | 469 | -42.0% | 0.02% | -46.7% |
Q1 2017 | $69,000 | -31.7% | 809 | -20.1% | 0.03% | -31.8% |
Q4 2016 | $101,000 | +38.4% | 1,013 | +57.3% | 0.04% | +33.3% |
Q3 2016 | $73,000 | +87.2% | 644 | +66.0% | 0.03% | +73.7% |
Q2 2016 | $39,000 | +143.8% | 388 | +126.9% | 0.02% | +137.5% |
Q1 2016 | $16,000 | -20.0% | 171 | -20.5% | 0.01% | -20.0% |
Q4 2015 | $20,000 | -28.6% | 215 | -33.6% | 0.01% | -37.5% |
Q3 2015 | $28,000 | – | 324 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |